{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:48:35Z","timestamp":1792540115172,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11910-024-01345-y","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T08:01:56Z","timestamp":1718092916000},"page":"255-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Huntington\u2019s Disease: Latest Frontiers in Therapeutics"],"prefix":"10.1007","volume":"24","author":[{"given":"Joseph","family":"Saade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"issue":"1","key":"1345_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primer. 2015;1(1):15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5.","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"1345_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/ene.15645","volume":"30","author":"I Rodr\u00edguez-Santana","year":"2023","unstructured":"Rodr\u00edguez-Santana I, Mestre T, Squitieri F, et al. Economic burden of Huntington disease in Europe and the USA: results from the Huntington\u2019s Disease Burden of Illness study. Eur J Neurol. 2023;30(4):1109\u201317. https:\/\/doi.org\/10.1111\/ene.15645.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1345_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington\u2019s disease: the Integrated Staging System. Lancet Neurol. 2022;21(7):632\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(22)00120-X. Report on integrated data-driven staging system for Huntington disease providing a framework for clinical trial design and population definition.","journal-title":"Lancet Neurol"},{"key":"1345_CR4","unstructured":"Sathe S. SHIELD-HD: first look at the data from the natural history study in people with Huntington\u2019s disease, HD-ISS Stages 0 through 3. https:\/\/chdifoundation.org\/2024-conference\/#sathe. Accessed 11 Apr 2024."},{"issue":"1","key":"1345_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3233\/JHD-220555","volume":"12","author":"JD Long","year":"2023","unstructured":"Long JD, Gantman EC, Mills JA, et al. Applying the Huntington\u2019s Disease Integrated Staging System (HD-ISS) to observational studies. J Huntingt Dis. 2023;12(1):57\u201369. https:\/\/doi.org\/10.3233\/JHD-220555.","journal-title":"J Huntingt Dis"},{"issue":"3","key":"1345_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366\u201372. https:\/\/doi.org\/10.1212\/01.wnl.0000198586.85250.13.","journal-title":"Neurology"},{"key":"1345_CR7","unstructured":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial | Movement Disorders | JAMA | JAMA Network. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2532012. Accessed 12 Apr 2024."},{"issue":"6","key":"1345_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","volume":"22","author":"E Furr Stimming","year":"2023","unstructured":"Furr Stimming E, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494\u2013504. https:\/\/doi.org\/10.1016\/S1474-4422(23)00127-8. Report on the most recent VMAT2 transported inhibitor approved for the treatment of chorea in HD.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1345_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(23)00163-1","volume":"22","author":"B Heim","year":"2023","unstructured":"Heim B, Seppi K. Valbenazine as treatment for Huntington\u2019s disease chorea. Lancet Neurol. 2023;22(6):459\u201360. https:\/\/doi.org\/10.1016\/S1474-4422(23)00163-1.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1345_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/mdc3.12483","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus deutetrabenazine for Huntington\u2019s disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4(4):582\u20135. https:\/\/doi.org\/10.1002\/mdc3.12483.","journal-title":"Mov Disord Clin Pract"},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coph.2015.07.005","volume":"24","author":"G McClorey","year":"2015","unstructured":"McClorey G, Wood MJ. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol. 2015;24:52\u20138. https:\/\/doi.org\/10.1016\/j.coph.2015.07.005.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"1345_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50(1):259\u201393. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"1345_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","volume":"36","author":"ME Rook","year":"2022","unstructured":"Rook ME, Southwell AL. Antisense oligonucleotide therapy: from design to the Huntington disease clinic. BioDrugs. 2022;36(2):105\u201319. https:\/\/doi.org\/10.1007\/s40259-022-00519-9.","journal-title":"BioDrugs"},{"issue":"10","key":"1345_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 2017;16(10):837\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(17)30280-6.","journal-title":"Lancet Neurol"},{"key":"1345_CR15","unstructured":"Mestre T. Emerging therapies to slow the progression of huntington disease. Practical neurology. https:\/\/practicalneurology.com\/articles\/2022-sept\/emerging-therapies-to-slow-the-progression-of-huntington-disease. Accessed 5 Mar 2024."},{"key":"1345_CR16","doi-asserted-by":"crossref","unstructured":"McColgan P, Thobhani A, Boak L, et al. Tominersen in adults with manifest Huntington\u2019s disease. N Engl J Med. Published online 2023. Report on the first ASO being tested in phase III trial for HD.","DOI":"10.1056\/NEJMc2300400"},{"key":"1345_CR17","unstructured":"Boak L, McColgan P. Understanding the treatment and off-treatment effects of tominersen in the Phase III GENERATION HD1 study. https:\/\/chdifoundation.org\/2022-conference\/. Accessed 5 Mar 2024."},{"key":"1345_CR18","unstructured":"Ionis\u2019 partner to evaluate tominersen for Huntington\u2019s disease in new Phase 2 trial | Ionis Pharmaceuticals, Inc. https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-partner-evaluate-tominersen-huntingtons-disease-new-phase. Accessed 5 Mar 2024."},{"issue":"2","key":"1345_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JHD-239001","volume":"12","author":"C Estevez-Fraga","year":"2023","unstructured":"Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington\u2019s disease clinical trials corner: August 2023. J Huntingt Dis. 2023;12(2):169\u201385. https:\/\/doi.org\/10.3233\/JHD-239001. (Morton J, ed).","journal-title":"J Huntingt Dis"},{"key":"1345_CR20","unstructured":"McColgan P. New fluid biomarker data from GENERATION HD1 and what it means for GENERATION HD2. https:\/\/chdifoundation.org\/2024-conference\/#margolin. Accessed 12 Apr 2024."},{"issue":"6","key":"1345_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41587-021-00955-y","volume":"39","author":"C Sheridan","year":"2021","unstructured":"Sheridan C. Questions swirl around failures of disease-modifying Huntington\u2019s drugs. Nat Biotechnol. 2021;39(6):650\u20132. https:\/\/doi.org\/10.1038\/s41587-021-00955-y.","journal-title":"Nat Biotechnol"},{"key":"1345_CR22","unstructured":"Panzara M. Innovations that led to SELECT-HD, a phase1b\/2a clinical trial of an allele-selective therapy for Huntington\u2019s disease. https:\/\/chdifoundation.org\/2022-conference\/#panzara. Accessed 6 Mar 2024."},{"key":"1345_CR23","unstructured":"Inc WLSU. Wave life sciences announces positive update from phase 1b\/2a SELECT-HD trial with initial results indicating allele-selective target engagement with WVE-003 in Huntington\u2019s disease. GlobeNewswire news room. Published September 20, 2022. https:\/\/www.globenewswire.com\/en\/news-release\/2022\/09\/20\/2519092\/0\/en\/Wave-Life-Sciences-Announces-Positive-Update-from-Phase-1b-2a-SELECT-HD-Trial-with-Initial-Results-Indicating-Allele-Selective-Target-Engagement-with-WVE-003-in-Huntington-s-Diseas.html. Accessed 6 Mar 2024."},{"key":"1345_CR24","unstructured":"Antisense therapy to treat Huntington\u2019s disease and spinocerebellar ataxia. 2023. https:\/\/www.youtube.com\/watch?v=doqp3nTO660. Accessed 27 Mar 2024."},{"key":"1345_CR25","unstructured":"Datson N. VO659, an allele-preferential CAG repeat-targeting ASO with therapeutic potential for individuals living with polyglutamine disease. https:\/\/chdifoundation.org\/2023-conference\/. Accessed 6 Mar 2024."},{"key":"1345_CR26","unstructured":"Vico Therapeutics B.V. A phase 1\/2a, Open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with spinocerebellar ataxia types 1, 3 and Huntington\u2019s disease. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05822908. Accessed 31 Dec 2023."},{"key":"1345_CR27","unstructured":"Therapeutics V. Vico therapeutics announces first patient dosed in phase 1\/2a clinical trial of VO659 in Huntington\u2019s disease and spinocerebellar ataxia types 1 and 3. VICO therapeutics. Published April 3, 2023. https:\/\/vicotx.com\/vico-therapeutics-announces-first-patient-dosed-in-phase-1-2a-clinical-trial-of-vo659-in-huntingtons-disease-and-spinocerebellar-ataxia-types-1-and-3\/. Accessed 5 Mar 2024."},{"issue":"4","key":"1345_CR28","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","volume":"17","author":"D Dash","year":"2020","unstructured":"Dash D, Mestre TA. Therapeutic update on Huntington\u2019s disease: symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics. 2020;17(4):1645\u201359. https:\/\/doi.org\/10.1007\/s13311-020-00891-w.","journal-title":"Neurotherapeutics"},{"issue":"10","key":"1345_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529\u201346. https:\/\/doi.org\/10.1038\/s41582-020-0389-4.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"1345_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/archneurol.2009.180","volume":"66","author":"SQ Harper","year":"2009","unstructured":"Harper SQ. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol. 2009;66(8):933\u20138. https:\/\/doi.org\/10.1001\/archneurol.2009.180.","journal-title":"Arch Neurol"},{"key":"1345_CR31","unstructured":"UniQure Biopharma B.V. A phase I\/II, randomized, double-blind, sham control study to explore safety, tolerability, and efficacy signals of multiple doses of striatally-administered rAAV5-miHTT total Huntingtin gene (HTT) lowering therapy (AMT-130) in early manifest Huntington\u2019s disease. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT04120493. Accessed 31 Dec 2023."},{"key":"1345_CR32","unstructured":"UniQure Biopharma B.V. A phase Ib\/II study to explore safety, tolerability, and efficacy signals of multiple ascending doses of striatally-administered rAAV5-mihtt total huntingtin gene (HTT) lowering therapy (AMT 130) in early manifest Huntington\u2019s disease. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05243017. Accessed 31 Dec 2023."},{"key":"1345_CR33","unstructured":"uniQure. Phase I\/II Clinical Trial of AMT-130 | Programs & Pipeline. uniQure. https:\/\/www.uniqure.com\/programs-pipeline\/phase-1-2-clinical-trial-of-amt-130. Accessed 6 Mar 2024."},{"key":"1345_CR34","unstructured":"uniQure announces update on phase I\/II clinical trials of AMT-130 gene therapy for the treatment of Huntington\u2019s disease | uniqure BV. https:\/\/uniqure.gcs-web.com\/news-releases\/news-release-details\/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene. Accessed 6 Mar 2024."},{"key":"1345_CR35","unstructured":"Margolin D. Update on phase I\/II clinical trial of AMT-130 gene therapy for the treatment of Huntington\u2019s disease. https:\/\/chdifoundation.org\/2024-conference\/#margolin. Accessed 12 Apr 2024."},{"key":"1345_CR36","unstructured":"ExoRNA bioscience. An open-label, dose escalation early phase 1 study of ER2001 intravenous injection in adults with early manifest Huntington\u2019s disease. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT06024265. Accessed 31 Dec 2023."},{"key":"1345_CR37","unstructured":"Bhattacharyya A. Identification and development of orally administered, CNS-penetrant small molecules that lower huntingtin protein levels by inducing a novel splicing event that alters the stability of huntingtin mRNA. https:\/\/chdifoundation.org\/2019-conference\/#bhattacharyya. Accessed 6 Mar 2024."},{"key":"1345_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41467-022-28653-6","volume":"13","author":"CG Keller","year":"2022","unstructured":"Keller CG, Shin Y, Monteys AM, et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat Commun. 2022;13:1150. https:\/\/doi.org\/10.1038\/s41467-022-28653-6.","journal-title":"Nat Commun"},{"issue":"1","key":"1345_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-240017","volume":"13","author":"C Estevez-Fraga","year":"2024","unstructured":"Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington\u2019s disease clinical trials corner: March 2024. J Huntingt Dis. 2024;13(1):1\u201314. https:\/\/doi.org\/10.3233\/JHD-240017.","journal-title":"J Huntingt Dis"},{"key":"1345_CR40","unstructured":"PTC518 phase 1 Huntington\u2019s disease program update | PTC Therapeutics, Inc. https:\/\/ir.ptcbio.com\/static-files\/2162ff85-c7ed-4555-8542-52fa2129f7fa. Accessed 27 Mar 2024."},{"key":"1345_CR41","unstructured":"PTC therapeutics shares positive interim data from PIVOT-HD clinical trial in Huntington\u2019s disease patients | PTC Therapeutics, Inc. https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-shares-positive-interim-data-pivot-hd-clinical. Accessed 6 Mar 2024."},{"issue":"6","key":"1345_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti A, Glass CK. The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol. 2015;36(6):364\u201373. https:\/\/doi.org\/10.1016\/j.it.2015.04.007.","journal-title":"Trends Immunol"},{"key":"1345_CR43","doi-asserted-by":"publisher","first-page":"1088124","DOI":"10.3389\/fimmu.2022.1088124","volume":"13","author":"Q Jia","year":"2022","unstructured":"Jia Q, Li S, Li XJ, Yin P. Neuroinflammation in Huntington\u2019s disease: from animal models to clinical therapeutics. Front Immunol. 2022;13:1088124. https:\/\/doi.org\/10.3389\/fimmu.2022.1088124.","journal-title":"Front Immunol"},{"key":"1345_CR44","doi-asserted-by":"publisher","first-page":"1238306","DOI":"10.3389\/fnins.2023.1238306","volume":"17","author":"S Yang","year":"2023","unstructured":"Yang S, Ma J, Zhang H, et al. Mutant HTT does not affect glial development but impairs myelination in the early disease stage. Front Neurosci. 2023;17:1238306. https:\/\/doi.org\/10.3389\/fnins.2023.1238306.","journal-title":"Front Neurosci"},{"issue":"11","key":"1345_CR45","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1038\/s41591-023-02566-3","volume":"29","author":"DK Wilton","year":"2023","unstructured":"Wilton DK, Mastro K, Heller MD, et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington\u2019s disease. Nat Med. 2023;29(11):2866\u201384. https:\/\/doi.org\/10.1038\/s41591-023-02566-3.","journal-title":"Nat Med"},{"issue":"6","key":"1345_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1091581817740873","volume":"36","author":"JA Lansita","year":"2017","unstructured":"Lansita JA, Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S. Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36(6):449\u201362. https:\/\/doi.org\/10.1177\/1091581817740873.","journal-title":"Int J Toxicol"},{"key":"1345_CR47","doi-asserted-by":"publisher","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A. Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis. 2022;14:117957352210925. https:\/\/doi.org\/10.1177\/11795735221092517.","journal-title":"J Cent Nerv Syst Dis"},{"key":"1345_CR48","unstructured":"Annexon, Inc. A phase 2a open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous ANX005 in subjects with, or at risk for, manifest Huntington\u2019s disease. clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT04514367. Accessed 31 Dec 2023."},{"issue":"Suppl 1","key":"1345_CR49","doi-asserted-by":"publisher","first-page":"A96","DOI":"10.1136\/jnnp-2022-ehdn.258","volume":"93","author":"R Kumar","year":"2022","unstructured":"Kumar R, Claassen DO, Mongan A, et al. J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington\u2019s disease (HD). J Neurol Neurosurg Psychiatry. 2022;93(Suppl 1):A96\u20137. https:\/\/doi.org\/10.1136\/jnnp-2022-ehdn.258. Report on phase 2 clinical trial of ANX005 as DMT for HD.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1345_CR50","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.nbd.2014.10.008","volume":"73","author":"ES Smith","year":"2015","unstructured":"Smith ES, Jonason A, Reilly C, et al. SEMA4D compromises blood\u2013brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis. 2015;73:254\u201368. https:\/\/doi.org\/10.1016\/j.nbd.2014.10.008.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1345_CR51","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/19420862.2015.1102813","volume":"8","author":"TL Fisher","year":"2016","unstructured":"Fisher TL, Reilly CA, Winter LA, et al. Generation and preclinical characterization of an antibody specific for SEMA4D. mAbs. 2016;8(1):150\u201362. https:\/\/doi.org\/10.1080\/19420862.2015.1102813.","journal-title":"mAbs"},{"key":"1345_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","volume":"76","author":"AL Southwell","year":"2015","unstructured":"Southwell AL, Franciosi S, Villanueva EB, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2015;76:46\u201356. https:\/\/doi.org\/10.1016\/j.nbd.2015.01.002.","journal-title":"Neurobiol Dis"},{"key":"1345_CR53","unstructured":"Vaccinex Inc. A phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with late prodromal and early manifest Huntington\u2019s disease to assess the safety, tolerability, Pk, and efficacy of pepinemab. clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/study\/NCT02481674. Accessed 31 Dec 2023."},{"key":"1345_CR54","doi-asserted-by":"publisher","unstructured":"Rodrigues FB, Wild EJ. Huntington\u2019s disease clinical trials corner: August 2018. J Huntingt Dis. 7(3):279\u2013286. https:\/\/doi.org\/10.3233\/JHD-189003.","DOI":"10.3233\/JHD-189003"},{"key":"1345_CR55","unstructured":"Evans E. Clinical development of VX15\/2503 anti-semaphorin 4D Antibody as a potential treatment for Huntington\u2019s disease. 2018 American Academy of Neurology (AAN) Annual Meeting. https:\/\/www.aan.com\/MSA\/Public\/events\/AbstractDetails\/36177. Accessed 2 Apr 2024."},{"issue":"10","key":"1345_CR56","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","volume":"28","author":"A Feigin","year":"2022","unstructured":"Feigin A, Evans EE, Fisher TL, et al. Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28(10):2183\u201393. https:\/\/doi.org\/10.1038\/s41591-022-01919-8.","journal-title":"Nat Med"},{"issue":"1","key":"1345_CR57","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-017-04990-1","volume":"7","author":"G Ellrichmann","year":"2017","unstructured":"Ellrichmann G, Blusch A, Fatoba O, et al. Laquinimod treatment in the R6\/2 mouse model. Sci Rep. 2017;7(1):4947. https:\/\/doi.org\/10.1038\/s41598-017-04990-1.","journal-title":"Sci Rep"},{"key":"1345_CR58","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc. A multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquinimod (0.5, 1.0 and 1.5 Mg\/Day) as treatment in patients with Huntington\u2019s disease. clinicaltrials.gov; 2020. https:\/\/clinicaltrials.gov\/study\/NCT02215616. Accessed 31 Dec 2023."},{"issue":"3","key":"1345_CR59","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1474-4422(23)00454-4","volume":"23","author":"R Reilmann","year":"2024","unstructured":"Reilmann R, Anderson KE, Feigin A, et al. Safety and efficacy of laquinimod for Huntington\u2019s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol. 2024;23(3):243\u201355. https:\/\/doi.org\/10.1016\/S1474-4422(23)00454-4.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1345_CR60","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/brain\/awz174","volume":"142","author":"R Kacher","year":"2019","unstructured":"Kacher R, Lamazi\u00e8re A, Heck N, et al. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington\u2019s disease. Brain. 2019;142(8):2432\u201350. https:\/\/doi.org\/10.1093\/brain\/awz174.","journal-title":"Brain"},{"key":"1345_CR61","unstructured":"Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio). An Open-label phase I\/II dose finding study to evaluate the safety, tolerability, and preliminary efficacy of striatal administration of AB-1001 in adult subjects with early manifest Huntington\u2019s disease (HD). clinicaltrials.gov; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05541627. Accessed 31 Dec 2023."},{"key":"1345_CR62","doi-asserted-by":"publisher","unstructured":"Sampaio C. Huntington disease \u2013 update on ongoing therapeutic developments and a look toward the future. Parkinsonism Relat Disord. 2024;122:106049. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106049. Paper with critical appraisal on current therapeutic landscape in HD and its challenges.","DOI":"10.1016\/j.parkreldis.2024.106049"},{"key":"1345_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2021.01.006","volume":"83","author":"R Tortelli","year":"2021","unstructured":"Tortelli R, Rodrigues FB, Wild EJ. The use of wearable\/portable digital sensors in Huntington\u2019s disease: a systematic review. Parkinsonism Relat Disord. 2021;83:93\u2013104. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.01.006.","journal-title":"Parkinsonism Relat Disord"},{"key":"1345_CR64","unstructured":"Huntington\u2019s disease therapeutics conference 2024 - day 3. HDBuzz. https:\/\/en.hdbuzz.net\/359. Accessed 4 Apr 2024."},{"key":"1345_CR65","unstructured":"Dorn J. Innovation in Huntington\u2019s disease clinical trial design. https:\/\/chdifoundation.org\/2024-conference\/#dorn. Accessed 11 Apr 2024."}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-024-01345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-024-01345-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-024-01345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:31:15Z","timestamp":1721295075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-024-01345-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s11910-024-01345-y","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"21 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. SAADE reports being a site co-PI for the WAVE trial.Dr. MESTRE reports being a site PI for GENERATION-HD1 trial (Roche), WAVE and PTC trials, in addition to consultation services for CHDI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}